Switzerland · Biotechnology startup
Switzerland · Memo Therapeutics
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.
Funding reportedLast round: Series C
What company datasets say Memo Therapeutics raised
Funding, as reported
Reported in all108.8Min the source's currency
Rounds7
Last roundSeries C
Last round dateMay 2024
Investors listed18
Founders and team
From Memo Therapeutics's own website: 8 on the team.
- Erik van den BergCEO, Board Member
- Lars SpengerCFO
- Alex BastianVP Commercial Strategy
- Kristie ClemmerVP Clinical Operations
- Matthieu DelincéVP Technology
- Ellen Rietmann AhlNon-Executive Director
- Lisanne van KouterikGeneral Counsel
- Michael CordesSenior Director Quality Management
On 4 portfolio pages
Investors who name them
Each firm lists Memo Therapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in Switzerland
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Memo Therapeutics in front of investors. Or tell us what we have wrong.